IRIS
TESTA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.648
Totale 8.648
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.648
Totale 8.648
Salva come PNG Salva come JPEG
Città #
Genova 6.578
Rapallo 870
Genoa 595
Vado Ligure 589
Bordighera 16
Totale 8.648
Salva come PNG Salva come JPEG
Nome #
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C 162
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 156
13C -Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. 154
Splanchnic haemodynamic effects of ketanserin in anaesthetized cirrhotic rats. 151
13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease 144
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 135
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. 133
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma 133
Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis 133
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 133
Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. 131
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice 130
Is there a role for multiple quantitative liver function tests? 127
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study 127
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 126
Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats 126
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? 126
Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C 125
The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis 122
Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 122
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 121
Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"? 120
Reply to Farinati et al.: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green 118
Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. 118
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 118
Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? 118
Propranolol reduces the response of serum bile acids to oral chenodeoxycholic acid, possibly as a reflex reaction to reduced portal blood flow in healthy and cirrhotic subjects. 117
Liver enzyme alteration: a guide for clinicians 117
Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients 115
Tryglycylvasopressin-reduced portal and systemic concentrations of serum bile acids after exogenous chenodeoxycholic acid load in rats as a reflection of reduced splanchnic blood flow 115
Is aspartate aminotransferase enough? 114
. Liver iron accumulation in chronic hepatittis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. 112
Influence of 1-week helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test 109
Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma 109
Two or more synchronous combination of noninvasive test to increase accuracy of liver fibrosis in chronic hepatitis C. 108
Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment 107
Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study 107
High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: Relationship with TNF-alpha levels 107
The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis 107
Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. 104
Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis 103
Can changing counseling strategy change the picture of the chronic hepatitis C patient population? 102
Eligibility criteria for antiviral therapy in HCV-positive patients: similar things to (almost) similar people 100
Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients 100
HOMA, BMI, and serum leptin levels variations during antiviral treatment suggest virus-related insulin resistance in noncirrhotic, nonobese, and nondiabetic chronic hepatitis C genotype 1 patients 100
Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis 99
13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis 96
Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C 92
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis 91
Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection 90
Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? 89
Caffeine clearance in subjects with constitutional un conjugated hyperbilirubinemia 87
Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. 86
Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C 86
Formation kinetics of the lidocaine metabolite (MEGX) in patients with chronic active hepatitis and cirrhosis 86
The metabolic syndrome: all criteria are equal, but some criteria are more equal than others. 85
Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have? 84
Analysis of circadian fluctuations of bile salt concentration and pH in the stomach of normal subjects and patients suspected of having duodenogastric reflux. 84
Non-invasive assessment of liver function: trying not to miss an opportunity. 83
Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. 83
Histological determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C 81
Effects of the association of lansoprazole, clarithromycin and metronidazole for Helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. 80
Progressive liver functional impairment is associated with an increase in AST/ALT ratio 80
Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastroesophageal reflux disease. 79
Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease 78
Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients 77
Wilson's disease with concomitant beta thalassaemia and factor V deficiency. 77
Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage 75
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 75
Chronic liver disease related to hepatitis C virus: age of patients seems to be a determinant of severity independently of viral genotype 74
Serum prolyl-hydroxylase as an index of fibrogenic activity in chronic active hepatitis and cirrhosis 73
Probability of non-response during interferon therapy in patients with chronic hepatitis C 72
Proposal and Validation of the AST/ALT ratio for predicting the presence of significant fibrosis in patients with chronic hepatitis C. 72
Inclusion of serum bile acids in Child-Turcotte-Pugh's score can improve grading assessment of alcoholic cirrhosis. 70
Postprandial serum bile acids after ursodeoxycholic acid. A possible test of intestinal absorption? 70
Omeprazole decreased formation of monoethylglycinexylidide in a patient with chronic active hepatitis. 68
Biochemical scores could reflect histological activity in chronic hepatitis C 66
The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. 65
Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. 63
Plasma aminoacid ratios in alcoholic cirrhotics with subclinical encephalopathy: relationships with cerebral blood flow. 63
Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. 60
13C-breath tests and liver fibrosis. 59
Oral or intravenous lidocaine administration to perform megx test? 59
Serum bile acid profiles after endogenous and exogenous loads of bile acid into the enterohepatic circulation of healthy subjects and patiens with chronic liver disease. 57
Long-term follow-up of chronic hepatitis C patients after interferon alpha treatment: a clinical and functional study 53
Malattie epatiche congenite 53
Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. 40
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 37
Totale 8.659
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.388
article - articoli 24.851
book - libri 0
conference - conferenze 200
curatela - curatele 0
other - altro 171
patent - brevetti 0
selected - selezionate 0
volume - volumi 166
Totale 50.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.612 0 0 0 0 0 247 338 119 186 395 232 95
2020/2021442 29 41 29 31 30 55 14 32 57 44 38 42
2021/20221.087 17 134 89 94 24 39 77 304 29 91 58 131
2022/20231.042 101 62 7 84 195 176 1 83 140 2 181 10
2023/2024408 18 68 8 57 35 48 13 29 14 5 43 70
2024/2025619 50 112 39 76 195 147 0 0 0 0 0 0
Totale 8.659